Site-specific crosslinking and assembly of tetrameric β-glucuronidase improve glycyrrhizin hydrolysis

In this study, eight nonconserved residues with exposed surfaces and flexible conformations of the homotetrameric PGUS (β-glucuronidase from Aspergillus oryzae Li-3) were identified. Single-point mutation into cysteine enabled the thiol-maleimide reaction and site-specific protein assembly using a two-arm polyethylene glycol (PEG)-maleimide crosslinker (Mal₂). The Mal₂(1k) (with 1 kDa PEG spacer)-crosslinked PGUS assemblies showed low crosslinking efficiency and unimproved thermostability except for G194C-Mal₂(1k). To improve the crosslinking efficiency, a lengthened crosslinker Mal₂(2k) (with 2 kDa PEG spacer) was used to produce PGUS assembly and a highly improved thermostability was achieved with a half-life of 47.2–169.2 min at 70°C, which is 1.04–3.74 times that of wild type PGUS. It is found that the thermostability of PGUS assembly was closely associated with the formation of inter-tetramer assembly and intratetramer crosslinking, rather than the PEGylation of the enzyme. Therefore, the four-arm PEG-maleimide crosslinker Mal₄(2k) (with 2 kDa PEG spacer) was employed to simultaneously increase the inter-tetramer assembly and intratetramer crosslinking, and the resulting PGUS assemblies showed further improved thermostabilities compared with Mal₂(2k)-crosslinked assemblies. Finally, the application of PGUS assemblies with significantly improved thermostability to the bioconversion of GL proved that the PGUS assembly is a strong catalyst for glycyrrhizin (GL) hydrolysis in industrial applications.     

Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency

Arginine deiminase (ADI) is a therapeutic protein for cancer therapy of arginine-auxotrophic tumors. However, its application as anticancer drug is hampered by its poor stability under physiological conditions in the bloodstream. Commonly, random PEGylation is being used for increasing the stability of ADI and in turn the improved half-life. However, the traditional random PEGylation usually leads to poor PEGylation efficiency due to the limited number of Lys on the protein surface. To boost the PEGylation efficiency and enhance the stability of ADI further, surface engineering of PpADI (an ADI from Pseudomonas plecoglossicida) to increase the suitable PEGylation sites was carried out. A new in silico approach for increasing the PEGylation sites was developed. The validation of this approach was performed on previously identified PpADI variant M31 to increase potential PEGylation sites. Four Arg residues on the surface of PpADI M31 were selected through three criteria and subsequently substituted to Lys, aiming for providing primary amines for PEGylation. Two out of the four substitutions (R299K and R382K) enhanced the stability of PEGylated PpADI in human serum. The average numbers of PEGylation sites were increased from ~12 (tetrameric PpADI M31, starting point) to ~20 (tetrameric PpADI M36, final variant). Importantly, the PEGylated PpADI M36 after PEGylation exhibited significantly improved T_m values (M31: 40°C; M36: 40°C; polyethylene glycol [PEG]-M31: 54°C; PEG-M36: 64°C) and half-life in human serum (M31: 1.9 days; M36: 2.0 days; PEG-M31: 3.2 days; PEG-M36: 4.8 days). These proved that surface engineering is an effective approach to increase the PEGylation efficiency which therefore enhances the stability of therapeutic enzymes. Furthermore, the PEGylated PpADI M36 represents a highly attractive candidate for the treatment of arginine-auxotrophic tumors.     

Anti-tumor activity and immunological modification of ribosome-inactivating protein （RIP） from Momordica charantia by covalent attachment of polyethylene glycol

Ribosome-inactivating proteins （RIPs） are a family of enzymes that depurinate rRNA and inhibit protein biosynthesis. Here we report the purification, apoptosisinducing activity, and polyethylene glycol （PEG） modification of RIP from the bitter melon seeds. The protein has a homogenous N-terminal sequence of N- Asp-Val-Ser-Phe-Arg. Moreover, the RIP displayed strong apoptosis-inducing activity and suppressed cancer cell growth. This might be attributed to the acti- vation of caspases-3. To make it available for in vivo application, the immunogenicity of RIP was reduced by chemical modification with 20 kDa （mPEG）2-Lys-NHS. The inhibition activity of both PEGylated and non- PEGylated RIP against cancer cells was much stronger than against normal cells, and the antigenicity of PEGylated RIP was reduced significantly. Our results suggested that the PEGylated RIP might be potentially developed as anti-cancer drug.     

Transfection efficiency of lipoplexes for site-directed delivery

Targeted gene delivery is a promising strategy to cure disease on its basic level at the site of interest. The ultrastructure, internalization, and transfection efficiency of lipoplexes was investigated. We found that at a charge ratio (ρ) of 4.0 lipoplexes had optimum characteristics for gene delivery in vitro. To decrease the size of lipoplexes, we used a method of continuous-flow microfluidics. PEGylation of lipoplexes did not hinder internalization, but was found to hamper transfection. To discriminate between uptake and transfection efficiency of lipoplexes, we used fluorescence-based approaches: microscopy and FACS. To this end, GFP plasmid was labeled with Alexa 594, and, in parallel experiments, GFP plasmid was combined with rhodamine-labeled lipid. Our studies confirm that cellular uptake does not imply transfection efficiency, and that hurdles in cellular processing have to be taken before targeted gene delivery becomes an established therapeutic option.     

Improved Fmoc‐solid‐phase peptide synthesis of an extracellular loop of CFTR for antibody selection by the phage display technology

Cystic fibrosis (CF), a life‐shortening genetic disease, is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that codes for the CFTR protein, the major chloride channel expressed at the apical membrane of epithelial cells. The development of an imaging probe capable of non‐invasively detect CFTR at the cell surface could be of great advantage for the management of CF. With that purpose, we synthesized the first extracellular loop of CFTR protein (ECL1) through fluorenylmethyloxycarbonyl (Fmoc)‐based microwave‐assisted solid‐phase peptide synthesis (SPPS), according to a reported methodology. However, aspartimide formation, a well‐characterized side reaction in Fmoc‐SPPS, prompted us to adopt a different side‐chain protection strategy for aspartic acid residues present in ECL1 sequence. The peptide was subsequently modified via PEGylation and biotinylation, and cyclized through disulfide bridge formation, mimicking the native loop conformation in CFTR protein. Herein, we report improvements in the synthesis of the first extracellular loop of CFTR, including peptide modifications that can be used to improve antigen presentation in phage display for selection of novel antibodies against plasma membrane CFTR.     

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation

Although antigen-binding fragments (Fabs) of antibodies constitute established tracers for in vivo radiodiagnostics, their functionality is hampered by a very short circulation half-life. PASylation, the genetic fusion with a long, conformationally disordered amino acid chain comprising Pro, Ala and Ser, provides a convenient way to expand protein size and, consequently, retard renal filtration. Humanized αHER2 and αCD20 Fabs were systematically fused with 100 to 600 PAS residues and produced in E. coli. Cytofluorimetric titration analysis on tumor cell lines confirmed that antigen-binding activities of the parental antibodies were retained. The radio-iodinated PASylated Fabs were studied by positron emission tomography (PET) imaging and biodistribution analysis in mouse tumor xenograft models. While the unmodified αHER2 and αCD20 Fabs showed weak tumor uptake (0.8% and 0.2% ID/g, respectively; 24 h p.i.) tumor-associated radioactivity was boosted with increasing PAS length (up to 9 and 26-fold, respectively), approaching an optimum for Fab-PAS₄₀₀. Remarkably, 6- and 5-fold higher tumor-to-blood ratios compared with the unmodified Fabs were measured in the biodistribution analysis (48 h p.i.) for αHER2 Fab-PAS₁₀₀ and Fab-PAS₂₀₀, respectively. These findings were confirmed by PET studies, showing high imaging contrast in line with tumor-to-blood ratios of 12.2 and 5.7 (24 h p.i.) for αHER2 Fab-PAS₁₀₀ and Fab-PAS₂₀₀. Even stronger tumor signals were obtained with the corresponding αCD20 Fabs, both in PET imaging and biodistribution analysis, with an uptake of 2.8% ID/g for Fab-PAS₁₀₀ vs. 0.24% ID/g for the unmodified Fab. Hence, by engineering Fabs via PASylation, plasma half-life can be tailored to significantly improve tracer uptake and tumor contrast, thus optimally matching reagent/target interactions.     

Effects of quaternization and PEGylation on the biocompatibility, enzymatic degradability and antioxidant activity of chitosan derivatives

Chitosan-N-trimethylaminoethylmethacrylate chloride (CS-TM) copolymers with different quaternization degrees (DQ, 30 and 50%) were synthesized and further modified with methoxypoly(ethylene glycol) (mPEG) of different molecular weights (MW, 2 and 5 kDa). The hydrophilicity of the resulting copolymers was significantly increased as evidenced by decreased contact angles. PEGylation with higher mPEG MW could significantly reduce the hemolytic potential, protein adsorption, cytotoxicity and intestinal mucosal damage of CS-TM (DQ of 50%, CS-TM50). PEGylation resulted in a considerable increase in the release of reducing sugars following 84-day lysozyme-catalyzed degradation, and an increase in mPEG MW led to a faster degradation of CS-TM50. The antioxidant activity of CS-TM50 was superior to that of PEGylated CS-TM50, exhibiting dose-dependent reducing power and lipid peroxidation inhibition effect. In conclusion, quaternization and subsequent PEGylation of CS with rational modification degree of its free amino group will be a potential strategy for the development of biocompatible and biodegradable CS derivatives.     

PEGylation kinetics of recombinant hirudin and its application for the production of PEGylated HV2 species

A critical challenge of PEGylation is the production of the desired PEGylated protein form at a high yield. In this study, a kinetic model was constructed successfully to describe the PEGylation reaction of recombinant hirudin variant-2 (HV2) with monomethoxy-PEG-succinimidyl carbonate (mPEG-SC) by fitting the experimental data. Moreover, PEGylation reaction conditions were investigated using the established model and the corresponding experiments to determine the optimal condition to achieve the mono-PEG-HV2 at the desired yield. The model predictions agreed well with the experimental data. Several important process parameters (maximum theoretical yield of mono-PEG-HV2 (y_max), critical PEG/HV2 molar ratio (m_crit) and reaction time to achieve y_max (t_max)) and their mathematical equations were obtained to determine the optimum reaction conditions. Among reaction conditions affecting the PEGylation rates, pH and temperature displayed little effect on y_max, but y_max increased as PEG size increased. Optimal reaction condition to produce mono-PEG-HV2 was as follows: pH and temperature could vary in a certain range; whereas PEG/HV2 molar ratio should be slightly greater than m_crit and the reaction should be stopped at t_max. The results of this study indicate that the proposed reaction kinetic model can provide a possible mechanism interpretation for real PEGylation reactions and optimize efficiently the PEGylation step.